Imprida, INN-Amlodipine besylate/valsartan - European Medicines Agency
SCIENTIFIC DISCUSSION
1. Introduction
M
ed
ic
in
a
lp
ro
du
ct
no
lo
ng
er
au
th
or
is
ed
The proper management and control of blood pressure in hypertension patients, and the impact it has
on associated morbidity and mortality rates, has been the focus of many new hypertension
observational studies and clinical trials. These trials have demonstrated that more aggressive blood
pressure lowering will reduce the complications associated with hypertension. As a result of this data,
international guidelines for the management of hypertension now recommend a target blood pressure
of ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- highlights of prescribing information amlodipine valsartan and
- exforge inn amlodipine valsartan european medicines agency
- µ amlodipine and valsartan tablets usp nf
- amlodipine valsartan and hydrochlorothiazide tablets type of posting
- imprida inn amlodipine besylate valsartan european medicines agency
- sds amlodilpne ans valsartan tablets march 2017 lupin
- amlodipine valsartan and hydrochlorothiazide tablets 5 mg 160 mg 12
- amlodipine valsartan and hydrochlorothiazide tablets
- fda approved patient labeling patient information and valsartan val
- exforge hct amlodipine valsartan hydrochlorothiazide label
Related searches
- amlodipine besylate recall 2019
- amlodipine besylate 5mg recall
- amlodipine besylate recall 2018
- amlodipine besylate 10 mg recall
- amlodipine besylate 10 mg
- amlodipine besylate 5 mg reviews
- amlodipine besylate 5 mg
- amlodipine besylate side effects in women
- amlodipine besylate 10 mg side effects
- amlodipine besylate 2 5 mg recall
- amlodipine besylate side effects complaints
- amlodipine besylate 10 40